GlycoEra

EpiBiologics

This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.

Lycia Therapeutics

The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.

Avilar Therapeutics

The company develops extracellular protein degraders to treat autoimmune and neurological diseases for patients and healthcare providers.

Dogma Biotech

This company develops AI-designed glycans to enhance protein therapeutic performance for patients with central nervous system and lysosomal storage diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Epana Bio

This company develops precision T-cell engagers and biologics using artificial intelligence and genomics to treat patients with autoimmune diseases.

Kyron.bio

This company develops glycan-engineering technology to improve therapeutic proteins and antibodies for pharmaceutical firms and research institutions.

Laigo Bio

This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.